Last reviewed · How we verify
JSKN016 Q3W
At a glance
| Generic name | JSKN016 Q3W |
|---|---|
| Sponsor | Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer (PHASE1, PHASE2)
- Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer (PHASE1, PHASE2)
- Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC (PHASE1)
- To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JSKN016 Q3W CI brief — competitive landscape report
- JSKN016 Q3W updates RSS · CI watch RSS
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd portfolio CI